Based on the "0 to 1" innovations made by the SystImmune R&D center, the Baili-Bio R&D center is responsible for the advanced development stages of innovative drug candidates. Meanwhile, the R&D team fully leverages "China Efficiency" to scale and accelerate translational medicine, preclinical development, and early clinical proof-of-concept validation. Leveraging the dual R&D center model established in the United States and China, a new drug R&D technology platform with independent intellectual property rights has been formed, providing a robust guarantee for continuous innovation. This strategy has enabled the company to establish world-class "end-to-end" ADC and multispecific antibody innovation R&D capabilities and competitive advantages.

Focus on Generic Drug R&D: This center leads the development of proprietary chemical formulations in anesthesia, parenteral nutrition, anti-infectives, and pediatrics. The company has made significant breakthroughs in investing in complex generic drug R&D, maintaining strict cost control while improving quality.